Kang Yu-Jian, Pan Lingjie, Liu Yiyu, Rong Zhengqin, Liu Jiaxi, Liu Fenglin
Chongqing Key Laboratory of Intelligent Oncology for Breast Cancer, Cancer Hospital, School of Medicine, Chongqing University, Chongqing 400030, China.
School of Life Sciences, Peking University, Beijing 100871, China.
Nucleic Acids Res. 2025 Jul 7;53(W1):W283-W290. doi: 10.1093/nar/gkaf423.
The GEPIA series has provided robust and widely used tools for pan-cancer analysis of gene expression data. In the post-genomic era, a major challenge lies in deconvoluting complex regulatory relationship influenced by multiple factors and discovering gene-based precision therapeutics. Here we present GEPIA3, an advanced version of GEPIA that provides a comprehensive analysis of gene/protein interactions across various cancer types. This version facilitates the investigation of treatment sensitivity utilizing both real-world patient data and cell line screens for over 1000 therapeutic agents, as well as the integration of RNA alterations derived from the pan-cancer analysis of whole genomes project. GEPIA3 represents a significant enhancement of the original platform, enabling in-depth exploration of gene regulation and cancer phenotypes, thereby supporting the identification of novel biomarkers and therapeutic targets. GEPIA3 is publicly accessible at https://gepia3.bioinfoliu.com.
GEPIA系列为基因表达数据的泛癌分析提供了强大且广泛使用的工具。在后基因组时代，一个主要挑战在于解析受多种因素影响的复杂调控关系，并发现基于基因的精准疗法。在此，我们展示GEPIA3，这是GEPIA的高级版本，它能对各种癌症类型中的基因/蛋白质相互作用进行全面分析。该版本有助于利用真实世界患者数据和针对1000多种治疗药物的细胞系筛选来研究治疗敏感性，以及整合来自全基因组泛癌分析的RNA改变。GEPIA3是对原始平台的重大改进，能够深入探索基因调控和癌症表型，从而支持新型生物标志物和治疗靶点的识别。可通过https://gepia3.bioinfoliu.com公开访问GEPIA3。
